<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:37:50 -0700</creation_date>
  <update_date>2013-01-15 20:37:50 -0700</update_date>
  <accession>HMDBP10771</accession>
  <secondary_accessions>
    <accession>17040</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Alpha-2 adrenergic receptor subtype C4</synonym>
    <synonym>Alpha-2C adrenoceptor</synonym>
    <synonym>Alpha-2C adrenoreceptor</synonym>
    <synonym>Alpha-2CAR</synonym>
  </synonyms>
  <gene_name>ADRA2C</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14362</accession>
      <name>Bethanidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14393</accession>
      <name>Cabergoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14413</accession>
      <name>Ropinirole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14557</accession>
      <name>Pramipexole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14627</accession>
      <name>Brimonidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14727</accession>
      <name>Lisuride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14835</accession>
      <name>Tizanidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14852</accession>
      <name>Apomorphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14938</accession>
      <name>Fenoldopam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15061</accession>
      <name>Phenoxybenzamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15317</accession>
      <name>Pergolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15396</accession>
      <name>Paliperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15464</accession>
      <name>Yohimbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15474</accession>
      <name>Methotrimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15517</accession>
      <name>Methamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15627</accession>
      <name>Droxidopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15640</accession>
      <name>Xylometazoline</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>alpha-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>alpha2-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4p16</locus>
    <gene_sequence>&gt;1389 bp
ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG
AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG
CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC
CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG
GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG
GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG
CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG
CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC
CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTCGCCGTGTGGCTCATCTCGGCC
GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC
GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC
ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC
GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC
GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG
TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG
CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG
CCCGGTGGCCGCCTCTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG
CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC
ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC
AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG
TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC
AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC
AGGCAGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>462</residue_number>
    <molecular_weight>49521.6</molecular_weight>
    <theoretical_pi>10.69</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>52-76</region>
      <region>89-114</region>
      <region>125-147</region>
      <region>169-191</region>
      <region>208-231</region>
      <region>380-407</region>
      <region>421-441</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Alpha-2C adrenergic receptor
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF
LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG
QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA
VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR
TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA
LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR
RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK
FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ</protein_sequence>
  </protein_properties>
  <genbank_protein_id>11055419</genbank_protein_id>
  <uniprot_id>P18825</uniprot_id>
  <uniprot_name>ADA2C_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1HOF</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AF280399</genbank_gene_id>
  <genecard_id>ADRA2C</genecard_id>
  <geneatlas_id>ADRA2C</geneatlas_id>
  <hgnc_id>HGNC:283</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Regan JW, Kobilka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK: Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6301-5.</reference_text>
      <pubmed_id>2842764</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schaak S, Devedjian JC, Cayla C, Sender Y, Paris H: Molecular cloning, sequencing and functional study of the promoter region of the human alpha2C4-adrenergic receptor gene. Biochem J. 1997 Dec 1;328 ( Pt 2):431-8.</reference_text>
      <pubmed_id>9371698</pubmed_id>
    </reference>
    <reference>
      <reference_text>Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB: A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000 Jul 28;275(30):23059-64.</reference_text>
      <pubmed_id>10801795</pubmed_id>
    </reference>
    <reference>
      <reference_text>Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, Liggett SB: Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13020-5. Epub 2004 Aug 19.</reference_text>
      <pubmed_id>15319474</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chhajlani V, Rangel N, Uhlen S, Wikberg JE: Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR. FEBS Lett. 1991 Mar 25;280(2):241-4.</reference_text>
      <pubmed_id>1849485</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Shreve PE, Toews ML, Bylund DB: Alpha 2A- and alpha 2C-adrenoceptor subtypes are differentially down-regulated by norepinephrine. Eur J Pharmacol. 1991 Jul 12;207(3):275-6.</reference_text>
        <pubmed_id>1654268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Rump LC, Bohmann C, Schaible U, Schollhorn J, Limberger N: Alpha 2C-adrenoceptor-modulated release of noradrenaline in human right atrium.  Br J Pharmacol. 1995 Nov;116(6):2617-24.</reference_text>
        <pubmed_id>8590979</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Bruck H, Schwerdtfeger T, Toliat M, Leineweber K, Heusch G, Philipp T, Nurnberg P, Brodde OE: Presynaptic alpha-2C adrenoceptor-mediated control of noradrenaline release in humans: genotype- or age-dependent? Clin Pharmacol Ther. 2007 Nov;82(5):525-30. Epub 2007 Apr 4.</reference_text>
        <pubmed_id>17410123</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Nash DT: Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol. 1990 Nov;13(11):764-72.</reference_text>
        <pubmed_id>1980236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Gilsbach R, Hein L: Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol. 2008;(184):261-88.</reference_text>
        <pubmed_id>18064417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bethanidine</name>
        <accession>HMDB14362</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bethanidine</name>
        <accession>HMDB14362</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bethanidine</name>
        <accession>HMDB14362</accession>
      </metabolite>
      <reference>
        <reference_text>Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationships between platelet alpha 2-adrenoceptors and sympathetic nerve activity in clinical hypertensive states. J Hypertens. 1990 Dec;8(12):1097-104.</reference_text>
        <pubmed_id>1962798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bethanidine</name>
        <accession>HMDB14362</accession>
      </metabolite>
      <reference>
        <reference_text>Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationship between platelet alpha 2-adrenoceptors and sympathetic nerve activity in man. Clin Exp Hypertens A. 1989;11 Suppl 1:287-94.</reference_text>
        <pubmed_id>2545383</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14.</reference_text>
        <pubmed_id>12388667</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pramipexole</name>
        <accession>HMDB14557</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brimonidine</name>
        <accession>HMDB14627</accession>
      </metabolite>
      <reference>
        <reference_text>Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11.</reference_text>
        <pubmed_id>14610637</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brimonidine</name>
        <accession>HMDB14627</accession>
      </metabolite>
      <reference>
        <reference_text>Orito K, Kishi M, Imaizumi T, Nakazawa T, Hashimoto A, Mori T, Kambe T: alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator. Br J Pharmacol. 2001 Oct;134(4):763-70.</reference_text>
        <pubmed_id>11606316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brimonidine</name>
        <accession>HMDB14627</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang W, Ordway GA: The alpha2C-adrenoceptor modulates GABA release in mouse striatum.  Brain Res Mol Brain Res. 2003 Apr 10;112(1-2):24-32.</reference_text>
        <pubmed_id>12670699</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brimonidine</name>
        <accession>HMDB14627</accession>
      </metabolite>
      <reference>
        <reference_text>Prinster SC, Holmqvist TG, Hall RA: Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther. 2006 Sep;318(3):974-81. Epub 2006 Jun 6.</reference_text>
        <pubmed_id>16757535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lisuride</name>
        <accession>HMDB14727</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tizanidine</name>
        <accession>HMDB14835</accession>
      </metabolite>
      <reference>
        <reference_text>Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702.</reference_text>
        <pubmed_id>8930173</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apomorphine</name>
        <accession>HMDB14852</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenoldopam</name>
        <accession>HMDB14938</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenoldopam</name>
        <accession>HMDB14938</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenoldopam</name>
        <accession>HMDB14938</accession>
      </metabolite>
      <reference>
        <reference_text>Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55.</reference_text>
        <pubmed_id>7670737</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6.</reference_text>
        <pubmed_id>11395517</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138024</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</reference_text>
        <pubmed_id>11132243</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Lalchandani SG, Lei L, Zheng W, Suni MM, Moore BM, Liggett SB, Miller DD, Feller DR: Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype. J Pharmacol Exp Ther. 2002 Dec;303(3):979-84.</reference_text>
        <pubmed_id>12438517</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Rizzo CA, Ruck LM, Corboz MR, Umland SP, Wan Y, Shah H, Jakway J, Cheng L, McCormick K, Egan RW, Hey JA: Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.  Eur J Pharmacol. 2001 Feb 16;413(2-3):263-9.</reference_text>
        <pubmed_id>11226402</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Cleary L, Murad K, Bexis S, Docherty JR: The alpha (1D)-adrenoceptor antagonist BMY 7378 is also an alpha (2C)-adrenoceptor antagonist. Auton Autacoid Pharmacol. 2005 Oct;25(4):135-41.</reference_text>
        <pubmed_id>16176444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Kalkman HO, Loetscher E: alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.  Eur J Pharmacol. 2003 Feb 21;462(1-3):33-40.</reference_text>
        <pubmed_id>12591093</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Cleary L, Vandeputte C, Docherty JR: Investigation of neurotransmission in vas deferens from alpha(2A/D)-adrenoceptor knockout mice. Br J Pharmacol. 2002 Jul;136(6):857-64.</reference_text>
        <pubmed_id>12110610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Coge F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A: Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse. 2000 Feb;35(2):79-95.</reference_text>
        <pubmed_id>10611634</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine.  Curr Med Res Opin. 2004 Dec;20(12):1877-81.</reference_text>
        <pubmed_id>15701205</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9.</reference_text>
        <pubmed_id>2870716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.</reference_text>
        <pubmed_id>6149771</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Jeng CH, Wang Y: Methamphetamine modulates GABA-induced electrophysiological depression by alternating noradrenergic actions in cerebellar Purkinje neurons. Psychopharmacology (Berl). 1998 Mar;136(2):132-8.</reference_text>
        <pubmed_id>9551769</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review.  Prog Neurobiol. 2005 Apr;75(6):406-33.</reference_text>
        <pubmed_id>15955613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Davis MP: Recent advances in the treatment of pain.  F1000 Med Rep. 2010 Aug 19;2:63.</reference_text>
        <pubmed_id>21173850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Giovannoni MP, Ghelardini C, Vergelli C, Dal Piaz V: Alpha2-agonists as analgesic agents.  Med Res Rev. 2009 Mar;29(2):339-68.</reference_text>
        <pubmed_id>18680204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Rump LC, Bohmann C, Schaible U, Schollhorn J, Limberger N: Alpha 2C-adrenoceptor-modulated release of noradrenaline in human right atrium.  Br J Pharmacol. 1995 Nov;116(6):2617-24.</reference_text>
        <pubmed_id>8590979</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Xylometazoline</name>
        <accession>HMDB15640</accession>
      </metabolite>
      <reference>
        <reference_text>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline.  Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi:       10.1111/j.1472-8206.2009.00805.x.</reference_text>
        <pubmed_id>20030735</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
